SAN JOSE, Calif., March 30, 2021 – BrightInsight, Inc., provider of the leading global regulated digital health platform for biopharma and medtech, today announced a Series C financing of $101M led by world-renowned venture capital firm General Catalyst. This funding will enable BrightInsight to accelerate its hypergrowth as it continues to expand its team, further differentiate its proven platform technology and support its customers’ digital health product launches globally. The Series C included strong participation from existing investors including Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies, New Leaf Venture Partners, a leading healthcare technology venture capital firm, and Eclipse Ventures, which invests in the digital transformation of essential industries, bringing the total raised to $166M.
BrightInsight continues to cement its position as the leading global regulated digital health platform for biopharma and medtech. Over the last year alone, BrightInsight and its biopharma clients launched three digital health products across various therapeutic areas. These include a high-risk Class C Software as a Medical Device (SaMD) algorithm, a rare disease patient support app, and more.
BrightInsight helps break down the silos that exist in today’s fractured healthcare system. The platform ensures that data is compliant, accessible and actionable across the healthcare ecosystem—enabling its customers to drive better outcomes, develop more personalized therapies, improve provider-patient engagement, and improve speed-to-market of life enhancing and life-saving therapies.
This latest round of financing enables BrightInsight to further invest in productizing the platform with robust, turnkey software modules that reduce customization for its customers. BrightInsight also plans to continue to grow its team across all departments, invest in customer success and expand the global availability of its platform across the Americas, China and other Asian markets.
“This financing led by General Catalyst not only validates the market need for a global digital health platform for biopharma and medtech, but it also reinforces the tremendous progress we have made in the past year,” said Kal Patel, MD, CEO & Co-Founder, BrightInsight. “Our Series C round will enable BrightInsight to continue our hypergrowth, and to support the development and launch of game-changing digital health solutions for our customers.”
“We believe BrightInsight can redefine biopharma and medtech’s approach to regulated digital health by providing the underlying platform technology to build and scale their programs,” said Hemant Taneja, Managing Director, General Catalyst. “Kal and the leadership team are addressing a pressing need and delivering a real benefit: allowing their customers to bring transformative digital health solutions to market more quickly and seamlessly.”
Taneja, who led the Series C deal, will be a close advisor to BrightInsight and will bring invaluable experience to the team as it scales. General Catalyst was an early investor in both fin-tech SaaS platform Stripe and digital health giant Livongo (co-founded by Taneja) which recently had the largest digital health exit in history at $18.5 Billion.
Dan Goldsmith, CEO, Tendo Systems, former CEO, Instructure, and former Chief Strategy Officer, Veeva, who had been serving as an advisor to BrightInsight, will join the BrightInsight Board of Directors.
BrightInsight is also bringing on an additional advisor to its recently established BrightInsight Advisory Council. Dr. Jeffrey Leiden, Executive Chairman of Vertex Pharmaceuticals, will join the Advisory Council to provide strategic and operational counsel to support and accelerate the company’s continued growth in order to meet the increased demand for its regulated platform.
ABOUT BRIGHTINSIGHT, INC.
BrightInsight provides the leading global regulated digital health platform for biopharma and medtech. When speed matters, we help leading companies accelerate time to market for regulated digital health offerings including apps, algorithms, medical devices, combination products, or Software as a Medical Device (SaMD) across therapeutic areas. BrightInsight replaces the need for lengthy and complicated ‘build from scratch’ implementations and instead offers a pre-built and proven platform developed under a Quality Management System to support global security, privacy, and regulatory requirements. When you build your digital health products on the BrightInsight Platform, you are future-proofing your highest-value offerings from a compliance standpoint and unlocking scaling opportunities that simply aren’t available without our agile approach. For more information, visit BrightInsight’s website, our blog, Twitter and LinkedIn pages.
ABOUT GENERAL CATALYST
General Catalyst is a venture capital firm that invests in powerful, positive change that endures — for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Datto, Deliveroo, Guild, Gusto, Hubspot, Illumio, Livongo, Oscar, Snap, Stripe, and Warby Parker. For more: https://www.generalcatalyst.com/
###
Media & Press
Jamie Burgess
VP, Marketing, BrightInsight
1.669.268.2838
jamie.burgess@brightinsight.com
Helen Shik
BrightInsight PR Firm
Shik Communications LLC
1.617.510.4373
Shik.helen10@gmail.com
Copyright © 2021 BrightInsight, Inc. BrightInsight and the BrightInsight logo are trademarks of BrightInsight, Inc. Other trademarks are the trademarks of their owners.